Marina Biotech Announces Proposed Public Offering of Common Stock and Warrants

Marina Biotech MRNA, a leading RNAi-based drug discovery and development company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as the sole manager for the offering. Marina Biotech intends to use the net proceeds of this offering for the clinical development of CEQ508, which is currently in a Phase 1b/2a clinical trial for the treatment of Familial Adenomatous Polyposis and for general corporate purposes, including working capital and operational purposes, including pre-clinical development.